Stock Analiz

Valneva SE VALN

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$5.66Market cap $537M
Open the interactive analysis →

Valneva SE (VALN) is a healthcare company listed in the US with a market value of about $537M. In the twelve months to June 30, 2026 it had revenue of $158M and net income of -$174M, a net margin of -110.3%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 9% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Valneva

Valneva is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $142M in 2019 to $205M in 2025, growth of about 6.4% a year. It was profitable in 0 of the last 7 years in our data.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 5-year revenue growth above 8% a year

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E4.8
P/FCF—
P/S3.4
P/B6.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.9%
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)16.5%
Revenue growth (5 yrs, per year)8.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-39.3%
ROIC (5-yr avg.)-19.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$158M$205M$176M$170M$385M$394M$135M$142M
Net income-$174M-$135M-$13M-$112M-$153M-$70M-$68M-$911082
Free cash flow-$64M-$67M-$84M-$240M-$293M-$17M$146M-$6M
EPS (diluted)$-1.95$-1.43$-0.13$-1.18$-1.61$-0.73$-0.71$-0.01
Net margin-110.3%-66.0%-7.2%-66.0%-39.7%-17.6%-50.0%-0.6%
ROIC—-22.7%2.9%-21.3%-35.2%-21.2%-41.6%-0.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Valneva stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Valneva pay a dividend?

Not currently.

Is Valneva a good stock to buy?

We do not give buy or sell advice. Valneva scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.